How to buy Vericel Corporation stock | $54.25

Vericel Corporation is a biotechnology business based in the US. Vericel Corporation shares (VCEL) are listed on the NASDAQ and all prices are listed in US Dollars. Vericel Corporation employs 273 staff and has a trailing 12-month revenue of around 0.00.

Vericel Corporation stock price (NASDAQ: VCEL)

Use our graph to track the performance of VCEL stocks over time.

Vericel Corporation shares at a glance

• Key figures

Information last updated 2021-07-30.

Latest market close	$54.25
52-week range	$14.45 - $68.94
50-day moving average	$56.36
200-day moving average	$52.11
Wall St. target price	$65.71
PE ratio	604.1573
Dividend yield	N/A (0%)
Earnings per share (TTM)	$0.09

Buy Vericel Corporation shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.

*Signup bonus information updated weekly.

Is it a good time to buy Vericel Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Technical Analysis of Vericel Corporation by TradingView

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Vericel Corporation price performance over time

Historical closes compared with the close of $54.25 from 2021-05-26

1 week (2021-07-23)	N/A
1 month (2021-07-02)	4.79%
3 months (2021-05-03)	-12.58%
6 months (2021-01-30)	N/A

1 year (2020-07-30)	N/A
2 years (2019-07-30)	N/A
3 years (2018-07-30)	N/A
5 years (2016-07-30)	N/A

Is Vericel Corporation under- or over-valued?

Valuing Vericel Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Vericel Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Vericel Corporation's P/E ratio

Vericel Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 604x. In other words, Vericel Corporation shares trade at around 604x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Vericel Corporation's EBITDA

Vericel Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.8 million.

The EBITDA is a measure of a Vericel Corporation's overall financial performance and is widely used to measure a its profitability.

Vericel Corporation financials

Revenue TTM	$132.1 million
Operating margin TTM	3.14%
Gross profit TTM	$84.2 million
Return on assets TTM	1.43%
Return on equity TTM	3.42%
Profit margin	3.24%
Book value	$3.03
Market capitalisation	$2.5 billion

TTM: trailing 12 months

Shorting Vericel Corporation shares

There are currently 3.4 million Vericel Corporation shares held short by investors – that's known as Vericel Corporation's "short interest". This figure is 6.8% down from 3.7 million last month.

There are a few different ways that this level of interest in shorting Vericel Corporation shares can be evaluated.

Vericel Corporation's "short interest ratio" (SIR)

Vericel Corporation's "short interest ratio" (SIR) is the quantity of Vericel Corporation shares currently shorted divided by the average quantity of Vericel Corporation shares traded daily (recently around 595209.53206239). Vericel Corporation's SIR currently stands at 5.77. In other words for every 100,000 Vericel Corporation shares traded daily on the market, roughly 5770 shares are currently held short.

However Vericel Corporation's short interest can also be evaluated against the total number of Vericel Corporation shares, or, against the total number of tradable Vericel Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Vericel Corporation's short interest could be expressed as 0.07% of the outstanding shares (for every 100,000 Vericel Corporation shares in existence, roughly 70 shares are currently held short) or 0.0827% of the tradable shares (for every 100,000 tradable Vericel Corporation shares, roughly 83 shares are currently held short).

A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Vericel Corporation.

Find out more about how you can short Vericel Corporation stock.

Vericel Corporation share dividends

We're not expecting Vericel Corporation to pay a dividend over the next 12 months.

Have Vericel Corporation's shares ever split?

Vericel Corporation's shares were split on a 1:20 basis on 15 October 2013. So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Vericel Corporation shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Vericel Corporation shares which in turn could have impacted Vericel Corporation's share price.

Vericel Corporation share price volatility

Over the last 12 months, Vericel Corporation's shares have ranged in value from as little as $14.45 up to $68.94. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Vericel Corporation's is 2.074. This would suggest that Vericel Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Vericel Corporation overview

Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts. .

Frequently asked questions

What percentage of Vericel Corporation is owned by insiders or institutions?
Currently 1.168% of Vericel Corporation shares are held by insiders and 113.207% by institutions. How many people work for Vericel Corporation?
Latest data suggests 273 work at Vericel Corporation. When does the fiscal year end for Vericel Corporation?
Vericel Corporation's fiscal year ends in December. Where is Vericel Corporation based?
Vericel Corporation's address is: 64 Sidney Street, Cambridge, MA, United States, 02139 What is Vericel Corporation's ISIN number?
Vericel Corporation's international securities identification number is: US92346J1088 What is Vericel Corporation's CUSIP number?
Vericel Corporation's Committee on Uniform Securities Identification Procedures number is: 00253U107